Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. The company is headquartered in Palo Alto, California. Show more
400 CONNELL DRIVE, BERKELEY HEIGHTS, NJ, UNITED STATES, 07922, Berkeley Heights, NJ, 07922, USA
Market Cap
97.6M
52 Wk Range
$2.55 - $11.88
Previous Close
$4.15
Open
$4.13
Volume
51,385
Day Range
$3.94 - $4.19
Enterprise Value
6.653M
Cash
43.17M
Avg Qtr Burn
-11.43M
Insider Ownership
8.81%
Institutional Own.
75.72%
Qtr Updated
06/30/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
TH103 Details Neovascular Age-Related Macular Degeneration (nAMD) | Phase 1/2 Data readout |